Methods for treating or preventing viral infection
AssigneesUnikum Therapeutics Aps, Aarhus University
InventorsMartin Roelsgaard JAKOBSEN, Renee VAN DER SLUIS, Rasmus Otkjær BAK
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for treating or preventing viral infection, or disease or complications associated with viral infection, in particular infection by a coronavirus or influenza virus, optionally SARS-CoV-2, SARS-CoV or MERS-CoV.
Claims16
A method of treating or preventing a disease in a subject comprising administering a plasmacytoid dendritic cell (pDC), or a composition comprising said cell, to the subject, wherein the disease is a viral infection, or a disease or complication associated with a viral infection.
The method of any one of the preceding claims, wherein the pDC is engineered by transformation with an exogenous construct which deletes or disrupts CD304.
The method of any one of the preceding claims, wherein the anti-viral and/or anti-inflammatory agent is administered simultaneously with the pDC, or at a suitable time interval subsequent to administration of the pDC;
- optionally wherein the time interval is at least around 4 hours, 8 hours, 12 hours, or 24 hours.
The method of any one of the preceding claims, wherein the anti-inflammatory agent is:
- (a) An IL-6 antagonist;
- optionally comprising an antibody specific for IL-6 or IL-6R, such as tocilizumab, sarilumab, siltuximab, sirukumab, clazakizumab, elsilimomab, or levilimab;
- (b) A corticosteroid, such as dexamethasone, hydrocortisone or methylprednisolone;
- (c) A non-steroidal anti-inflammatory drug (NSAID), such as ibuprofen.
The method of any one of the preceding claims, wherein the virus is a coronavirus or influenza virus, optionally SARS-CoV-2, SARS-CoV or MERS-CoV, optionally wherein the disease is COVID-19.
The method of any one of the preceding claims, wherein the pDC is a stem cell-derived pDC.
The method of any one of the preceding claims, wherein the pDC expresses IFN type I and/or IFN type III cytokines.
A pDC, or a composition comprising said cell, as defined in any one of the preceding claims, optionally for use in a method of treating or preventing a viral infection or a disease or complication associated with a viral infection.
A method of generating a composition comprising a pDC comprising:
- (a) providing hematopoietic stem progenitor cells (HSPCs);
- (b) incubating said HSPCs in one or more media comprising cytokines, growth factor and/or interferons (IFNs), whereby said HSPCs are differentiated into precursor-pDCs and into pDCs incubating said HSPCs in one or more media, which media may comprise one or more cytokines, growth factors, interferons (IFNs) and/or aryl hydrocarbon receptor (1) antagonists (such as stemregenin-1), whereby said HSPCs are differentiated into precursor-pDCs and into pDCs;
- and
- (c) transforming said HSPCs prior to differentiation, or transforming said pDCs subsequent to differentiation, with an exogenous construct which prevents or reduces IL-6 expression or which prevents or reduces CD304 expression.
Dependencies are inferred from the claim text.